ProfileGDS5678 / 1422188_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 44% 44% 45% 42% 46% 43% 43% 44% 44% 44% 42% 43% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0689244
GSM967853U87-EV human glioblastoma xenograft - Control 23.0265944
GSM967854U87-EV human glioblastoma xenograft - Control 33.0287244
GSM967855U87-EV human glioblastoma xenograft - Control 42.9839545
GSM967856U87-EV human glioblastoma xenograft - Control 52.9243442
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1681546
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0690243
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9916743
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0010644
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0177944
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0107844
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9441642
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0126543
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0186544